GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer

  • End date
    Jun 16, 2022
  • participants needed
  • sponsor
    Fudan University
Updated on 16 August 2021


Study design: Prospective, single-arm, single-center study; Primary endpoint: Safety; Secondary endpoints: Disease control rate, overall response rate, conversion rate, overall survival; Main characteristics of enrolled patients: Patients with initially unresectable biliary tract cancer; Interventions: Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab; Sample size: 10 patients;

Treatment until:

  1. successfully conversed to resectable disease
  2. progressed disease
  3. intolerable toxicity
  4. patient requests withdrawal Research process: In this study, patients who met the inclusion criteria were evaluated at the end of every 2 circles of treatment (6 weeks), up to surgical treatment or disease progression.

Safety evaluation: Evaluate adverse reactions according to CTCAE 4.0; Follow up: 12 months after the last case was enrolled.

Condition Biliary Tract Carcinoma
Treatment Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab
Clinical Study IdentifierNCT04979663
SponsorFudan University
Last Modified on16 August 2021


Yes No Not Sure

Inclusion Criteria

Age 18 years and 80 years
ECOG physical condition score: 0~1
Histologically or cytologically confirmed malignant tumor of epithelial origin in the biliary system
Preoperative imaging assessment of the disease stage was III/IV
The main organs function well, and the examination indicators meet the following
Routine blood tests: Hemoglobin 90 g/L (no blood transfusion within 14 days)
Neutrophil count 1.510^9/L; Platelet count 8010^9/L; Biochemical examination
Total bilirubin 2ULN (upper normal value); ALT or AST 2.5ULN; Endogenous
creatinine clearance 50 mL /min (Cockcroft-Gault formula); 6. Sign the
informed consent voluntarily; 9. Good compliance, and family members willing
to cooperate with follow-up

Exclusion Criteria

Patients with other uncured malignant tumors
Pregnant or lactating women who are required to withdraw from the clinical trial if they become pregnant during the study period
Previous antitumor therapy for the disease in this study
Participated in clinical trials of other drugs within one month
Patients with a known history of other systemic serious diseases before screening
Long-term unhealed wounds or incomplete healing fractures
Previous organ transplantation history
Abnormal coagulation function
Screening for overactivity/venous thrombosis events in the previous year, such as cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis and pulmonary embolism
Having a history of abuse of psychotropic substances and being unable to quit or having mental disorders
A history of immune deficiency or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation
Concomitant conditions that, in the investigator's judgment, seriously endanger the patient's safety or affect the patient's completion of the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note